

Commercial Support

This activity was sponsored by an educational grant from Novo Nordisk.

2



Faculty and Disclosure Statement

Angela is a current fellow and past president of the American Association of Nurse Practitioners (AAMP). Her tenure as the president of the AAMP gives her a unique and overarching perspective of the multifunctional role of the Nurse Practitioner. She is also a Fellow of the Obesity Medicine Association.

Fractuoties, are is also shown on the close of the reaction of the close of the clo

Disclosures: • Consultant: Novo Hordisk • Advaor: Greiszi Biotechnology, Currax Pharmaceuticals, El Lilly and Company, Vivus • Speaker's Bureaux: Currax Pharmaceuticals, Novo Rordisk, Vivus



Faculty and Disclosure Statement


Amy is a nationally respected obesity medicine PA. She has received the highest level of training in obesity medicine for PAs, receiving the Advanced Education of Obesity Medicine from the Obesity Medical Association. This distinction demonstratics here extensive knowledge of exidence-based obesity treatment approaches and an ongoing commitment to patient health.


Communent to patient mean: Beyond the office, Any is immersed in helping to advocate and expand the understanding and complexity of obesity as a chronic disease. She is founder of the PAs in Obesity Medicine special interest group, as well as prevident and founder of the Arizona Obesity, Organization. She is a guest lecturer at Yale School of Medicine Ohline PA Program on obesity medicine. More than anything, the appreciates being able to help educate other healthcare providers on how to provide optimal evidence-based care for individuals with pre-obesity and obesity.

Novo Nordisk: speakers' bureau for type 2 diabetes and obesity

2022 AAPA, TOS, NACE. All rights reserved.

4







10/19/22



7

Intake

- Susan, a 36-year-old woman, arrives at the office for a new patient intake • She is new to the area and is
- establishing for primary care
- All new patients have a measured height
- The MA notes a BMI of 34 kg/m² this triggers the system in place
- In the room, the MA explains to the patient that a new "vital sign" has been added a waist circumference
 Waist circumference (WC) is 40"

8

How to Perform Waist Circumference Measurement • Patient should be standing with arms hanging at his/her sides • Place tape measure on bare skin with measuring tape that doesn't easily stretch • Locate upper hip bone and top of the right iliac crest • Place tape parallel to floor around abdomen through top of left iliac crest • Keep tape snug, but not tight • Measure at end of expiration



Intake

PMH

- . Migraines, DM, HTN, osteoarthritis, asthma
- SH: married with one child 8 years old; works as an accountant part time
- · Pregnancy prevention plan: husband had vasectomy
- FH: all family members are heavy and most have DM, HTN; dad had an MI; no cancer history
- Medications
 - Sumatriptan prn (uses 10-15 times a month)
 - Sumatriptan pm (USE 3 up 3 umes a montu)
 Proprianoli 80 mg RF for headache prevention (started 2 months ago before leaving previous practice)
 Losartan 50 mg, HCT 21.5mg
 Ibuproffen daily 800 mg BID
 Albuterol inhaler pm, uses 5-6 times a month

 - Montelukast 10 mg daily

 - Metformin 2000 mg ER
 Empagliflozin 10 mg qam (started 2 months ago)
- BID, twice a day; DM, diabetes mellitus; ER, extende

10


Intake

- General: Generally able to accomplish all activities of daily living; works as a medical assistant; no change in strength or exercise tolerance
- Head: No headaches, no vertigo
- Eves: Normal vision, no diplopia
- Chest: No dyspnea; has not used inhaler in past 4 weeks
- · Heart: No chest pains, no palpitations, no syncope, no orthopnea
- Abdomen: No dysphagia, no abdominal pains, no bowel habit changes, no emesis
- Neurologic: No weakness, no tremor, no seizures, no changes in mentation; has not needed sumatriptan
 in past month
- · Endocrine: No changes in skin, no excessive thirst or urination
- Psychiatric: No depressive symptoms, no changes in sleep habits, no changes in thought content Sleep: Wakes feeling tired every day
- Pain: Knees are painful when walking daily

11

Intake

- VS: BP 130/88 mmHg; HR 80 bpm; RR 16; Height 66"; Weight 211 lbs; BMI 34 kg/m²
- General: patient in NAD, cooperative with examiner, well groomed, alert and oriented x 4
 Eyes: PERRLA, conjunctivae clear, no discharge; Fars: Canals clear bilaterally, TMs norma bilaterally; Nose: Moist, pink mucosa without lesions or mass; Throat: no exudates, no erythema; Fundoscopic exam: Disc margins are sharp, cup to disc ratio <50%, no AV nicking, no exudates or hemorrhages noted
- Neck: Supple, no masses, no thyromegaly, no bruits, no lymphadenopathy
 Chest: BSCTA bilaterally, no rales, no rhonchi, no wheezes, speaking in full sentences, respirations nonlabored
- Heart/CV: RR, no rubs, no gallops; radial and pedal pulses 2+ equal bilaterally
- Abdomen: bowel sounds normal, percussion tones normal, SNT without rebound, no masses, no hepatomegaly Neuro: alert and oriented x 4, CN II-XII grossly intact, stable gait, Romberg negative, DTRs 2+ equal bilaterally, recent and distant memory grossly intact
- Extremities: Warm, well perfused, no edema, grips and pushes 2+ equal bilaterally
- Skin: no noted acanthosis nigricans, no striae
- AV, arteriovenous; BP, blood pressure; bpm, beats per minute; BSCTA, breath sounds clear to auscultation; CN, cranial nerves; CV, cardiovascular; DTR, deep tendon rate; NAD, no apparent distress; PERRLA, pupils, equal, round, reactive, light, accommodation; RR, respiratory rate; SVT, soft, non-tender; TM, temporal membrane.













 Weight stigma refers to the discriminatory acts and ideologies targeted toward individuals because of their weight and size
 Weight bias refers to the negative ideologies associated with obesity

Weight stigma is a result of weight bias

17

Weight Bias



 Weight bias and stigma can: Impact approach clinically Limit reimbursement


 Can keep patients from seeking healthcare Resulting in increased morbidity and mortality


Weight Stigma




"Experiencing weight stigma undermines health by contributing to obesity, metabolic disease, psychological disorders, and ultimately mortality."

19









Visit 1

• VS: BP 136/82 mmHg; HR 82 bpm; RR 16; Height 5'6"

Weight history

- Patient has been as high as 300 lbs; has been attending WW for past 4 months did this Finds she has cravings for food most evenings, especially sweets
- No specific activity walks about 3000 steps a day using her watch to monitor, but can't walk more as it is too painful
- Review labs from previous provider done 2 months ago
 - Dyslipidemia (patient unaware): total cholesterol is 245 mg/dL, LDL is 134 mg/dL, triglycerides 192 mg/dL, HDL 38 mg/dL

 - DM: HbA1c 7.2
 Liver enzymes: AST 23 U/L, ALT 26 U/L

23

Visit 1

• Medications

- Medications Sumatriptan prn (uses 10-15 times a month) Propranolo 80 mg ER for headache prevention (started 2 months ago before leaving previous practice) Losartan 50 mg, HCT 21.5 mg Ibuprofen daily 800 mg bid Albuterol inhaler prn, uses 5-6 times a month Montelukast 10 mg daily Metformin 2000 mg ER Empagifikozin 10 mg qAM (started 2 months ago) Erropagifikozin 10 mg qAM (started 2 months ago)


- Screening tools: PHQ-9 3, BED-7 0, STOP-BANG 5, PAR-Q pain in knees
- PE: Patient is alert and oriented x 4, recent and remote memory intact, breathing is nonlabored, patient speaking in full sentences, radial pulse has RRR, skin is normal color, capillary refill is < 2 seconds, gait is normal
- Assessment: migraines, DM, HTN, osteoarthritis, asthma, hyperlipidemia, obesity BED-7, Binge -7; PE, phy


	Polling Question	?
What class and stage would Susan's obesity be classified as?	A. Class 1, Stage 2B. Class 2, Stage 1C. Class 2, Stage 2D. Class 3, Stage 3	
	Copyright © 2022 AAPA, TOS, NACE. All rights reserved.	

Visit 1

- Assessment: migraines, DM, HTN, osteoarthritis, asthma, hyperlipidemia, obesity
- Medications: sumatriptan, propranolol, losartan, ibuprofen, albuterol inhaler, montelukast, metformin, empagliflozin
- Screening tools: PHQ-9 3, BED-7 0, STOP-BANG 5, PAR-Q pain in knees
 PE: Patient is alert and oriented x 4, recent and remote memory intact, breathing is nonlabored, patient speaking in full sentences, radial pulse has RRR, skin is normal color, capillary refill is <2 seconds, gait is normal

26

















Visit 2 History ROS: no changes, has not had to use abbuterol or sumatriptan ROS: no changes, has not had to use abbuterol or sumatriptan VS: BP 128/82 mm Hg; HR 78 bpm; RR 16; 02 98%; Weight 207 lbs; BMI 33.41 kg/m² PE: Pattent is alert and oriented x 4, recent and remote memory intact, breathing is nonlabored, patient speaking in full sentences; radial pulse has RRA, skin is normal color, capillary reffit is <2 seconds, gait is normal FBS: range 98-168 mg/dL, 2-hour postprandial 200-210 mg/dL Assessment Medications Sumatripting nr (uses 10-15 times a month) Loards Dorng HdW (uses 10-15 times a month) Iburyofen daily 800 mg ibd Rober (naler Inhaler an eded, uses 56 times a month) Montroliduat 10 mg edW (tasted 2 months ago) Empagifican 10 mg edW (tasted 2 months ago)



Medical/Clinical

- Discuss anti-obesity medication (AOM) for intensification of obesity treatment
- Increase empagliflozin to 25 mg Has Susan scheduled appointment from sleep apnea referral?



35

Nutrition

- Review food log eats fast food 3-4 times a week, drinks NSS beverages 32 ounces a day, CHO 330 g average, protein 35 g, calories 1500-2800 range
- Handouts protein grams and protein snacks, hunger scale,
- medication handout
- Determine food plan

 - Selecting a plan or <u>modification process</u>
 30 grams of protein with breakfast
 Decrease CHO to less than 200 g use log to teach what a CHO is
 Needs to monitor hunger for next visit

ate; NSS, non-sugar sweetened beverages; PRO, pro


Physical Activity



Review physical activity – averaging 3000 steps a day
Has Susan scheduled appointment from referral for physical therapy?

tht © 2022 AAPA, TOS, NACE, All I

37



Schedule Follow Up				
Follow-up visit in 2 weeks				



Visit 3

- History
 Go over tracking of food and water initiale, increase of empagifilicain
 Vs: SiP 126/64 mmHg; HR 80 bpm; RR 16; O2 97%; 204 lbs; BMI 32.92 kg/m:
 History
 • ROS: no changes, has not had to use allottered or sumatriptan
 PE: Patient is galert and originate day. 4, excert and greenote
 Precover a set of the set of th

41

Pillars of Care Review

Medical/Clinical

- Evaluate patient hunger and discuss the use of medication to impact the hormonal dysregulation
 Patient reports hunger still high, especially at night
- Ask about asthma any use of rescue inhaler? (no)
- Ask about migraines any need for sumatriptan (once in past week)
- Blood sugars improving and tolerating increase of empagliflozin with no issues

43

	R	x	A	0	м
iraglutide	Cost – will need patient to check coverage	No history of cancer or MENS	Diabetes without control	If 3 mg not approved could prior auth the lower dose for diabetes	✓
Naltrexone/ oupropion	\$99/month	HTN is controlled, no selzure disorder or eating disorder, no opioid use	Cravings for sweet foods in evening Possibly depression but will need to monitor closely		\checkmark
Orlistat	OTC ~31/month RX ~\$450/month	No contraindication			Patient concerned about GISE
Phentermine	Low cost			Long-term use	\checkmark
Phentermine/ topiramate	\$98/month if not covered	No glaucoma, hyperthyroidism, no MAOI	Migraine prophylaxis	Could use just topiramate off label	\checkmark
Semaglutide	Cost – will need patient to check coverage	No history of cancer or MENS	Diabetes without control	If 2.4 mg not approved could prior authorization the lower dose for diabetes	\checkmark


44

	Polling Question	?
What medication is your first choice for Susan?	A. LiraglutideB. Naltrexone/bupropionC. PhentermineD. Phentermine/topiramateE. Semaglutide	

Nutrition


- Had 30 g protein 5 days of 7 not on weekends
- Review SMART goal any roadblocks CHO under 200 g every day
- Revisit eating decisions modifications with SMART goals versus meal plan
 Continue with modifications Could decrease fast food or continue to decrease carbohydrate load


46




Behavioral Create SMART goal around eating for next 2 weeks (c) • Continue to decrease carbohydrates – new goal 150 g; use diary to find more places to decrease CHO Intensive lifestyle interventions (ILI) – select an education handout for today; 5-minute review of the handout











































































Visit: Chronic Management (Indefinite)





 Visits (Indefinite) – All Pillars

 Review ACM, adjust as needed
 Review nutrition log
 Review SMART goal/behavioral change
 Review physical activity goals

 Review for obsogenic medications
 Review referrats (if needed)
 Order labs (if needed)
 Ack Individual when they would like to see you back for follow up

 Chronic, long-term management
 Chronic to the to the dual game
 Chronic to the total game


80


Metabolic Adaptation




















References / Resources

- Adult Obesity Algorithm eBook: Detailed overview of Obesity Medicine Bays HE, McCarthy W, Christensen S, Tondt J, Karjoo S, Davisson L, Ng J, Golden A, Burridge K, Conroy R, Welk S, Umashanker D, Afreen S, Delesus R, Salter D, Shah N. Obesity Algorithm eBook, presented by the Obesity Medicine Association, <u>awww.obesitvaleovithm.org</u>. accessed 01 January 2021, <u>https://obesitymedicine.org/obesity-algorithm/</u>. .
- Rethink Obesity, accessed 01 August 2020, <u>https://www.rethinkobesity.com/resources.htm</u>l. Information for Information for Healthcare Providers & Patients, accessed 20 July 2020, <u>https://www.obesity.org/information-for-patients/</u>
- •
- national. Prestment Algorithms for the Medical Care of Patients With Obesity accessed 24 July 2020. https://www.acce.com/disease-state-resources/nutrition-and-obesity/treatment-aleorithms/treatment-aleorithm-medical-care. Exercise is Medicine Prescription Tool and Referral, accessed 18 January 2021, https://www.exercisemedicine.org/standard/upcont cares enh/elime.evercise-prescription-and-referral-top//. Tang QL 1X, Song P, XuL: Optimal Cut-Off values for the homeostasis model assessment of insulin resistance (HOMA-IR) and pre-diabetes strenging. Developments in research and prospects for the future. *Drug Discov Ther.* 2015 Dec;9(6):380-385. doi: 10.5582/doit.2015.01207. PMID: 26781921. .

HT IC 2022 AAPA TOS NACE ALL